import Navbar from '@/components/Navbar';
import Footer from '@/components/Footer';
import { Link } from 'react-router-dom';
import { SEOHead } from '@/components/seo/SEOHead';
import { BreadcrumbNav } from '@/components/seo/BreadcrumbNav';
import { FAQSection } from '@/components/healthcare-research/FAQSection';
import { buildBreadcrumbSchema } from '@/lib/seo/schemas';
import { getStandaloneReportConfig } from '@/data/reportConversionConfig';
import { MarketIntelligenceSections } from '@/components/market-intelligence';
import { buildReportEnrichmentSchemas } from '@/lib/reportEnrichmentSchemas';
import {
  ReportConsultationBand,
  ReportContentWithAside,
  ReportMidPageCta,
  ReportReadingProgress,
} from '@/components/report-conversion';
import { ReportPremiumHero } from '@/components/report-premium';
import { finalizeStandaloneHealthcareFaqs } from '@/data/standaloneCountryReportContent';

const breadcrumbItems = [
  { name: 'Home', href: '/' },
  { name: 'France Healthcare Market Report', href: '/france-healthcare-market-report' },
];

const REPORT_FAQ_ITEMS = finalizeStandaloneHealthcareFaqs([
  {
    question: 'How big is the France healthcare market in 2026?',
    answer: 'The French healthcare market is estimated at EUR 255–270 billion in 2026, representing approximately 12.1% of GDP. France operates a universal healthcare system (Assurance Maladie, colloquially called "la Sécu") funded through payroll contributions and general taxation. Approximately 77% of healthcare costs are covered by the Assurance Maladie (CNAM), with complementary insurance (mutuelles and assurances complémentaires) covering an additional 13% on average, leaving approximately 10% as out-of-pocket expenditure. France has approximately 3,000 hospitals (public and private), 74,000 community pharmacies, and 220,000+ physicians.',
  },
  {
    question: 'What is the France pharmaceutical market size in 2026?',
    answer: 'The French pharmaceutical market is estimated at EUR 32–35 billion in 2026, making it the second-largest pharmaceutical market in the EU after Germany. The Assurance Maladie reimburses approved medicines at rates ranging from 15% to 100% depending on therapeutic value. HAS (Haute Autorité de Santé) Transparency Commission assesses all new medicines for SMR (Service Médical Rendu, medical benefit) and ASMR (Amélioration du Service Médical Rendu, improvement of medical benefit), with ASMR ratings I–V (I = major improvement, V = no improvement demonstrated). Price negotiations for reimbursed products are conducted by CEPS (Comité Économique des Produits de Santé).',
  },
  {
    question: 'How does HAS market access work for pharmaceuticals in France?',
    answer: 'The French HAS (Haute Autorité de Santé) Transparency Commission conducts benefit assessment for all new medicines seeking reimbursement. The two-stage assessment assigns: (1) SMR (medical benefit level) — the absolute benefit rating (major/important/moderate/low/insufficient) that determines reimbursement rate; and (2) ASMR (improvement of medical benefit) — the comparative added benefit against the comparator (ratings I–V). Products with ASMR I–III typically receive a price premium versus existing treatments. Products with ASMR IV or V are generally priced at or below the comparator. Early access (Autorisation d\'Accès Précoce, AAP — replacing the former ATU system) enables HAS-assessed pre-approval access for promising therapies. Price negotiations with CEPS follow HAS assessment.',
  },
  {
    question: 'What are the largest therapy areas in the France pharmaceutical market?',
    answer: 'The five largest therapy areas in the French pharmaceutical market by Assurance Maladie reimbursement spend are: oncology (fastest-growing, driven by immunotherapy, targeted therapy, and cancer hospital budgets); cardiovascular (high volume: statins, anticoagulants, antihypertensives); immunology and biologics (TNF inhibitors, IL-17/23 inhibitors, JAK inhibitors, with growing biosimilar penetration); diabetes (GLP-1 agonists growing rapidly, insulin at high volume); and respiratory (COPD biologics, dupilumab for severe asthma, ICS/LABA combinations). The AAP early access pathway is particularly active in oncology and rare diseases.',
  },
  {
    question: 'What is the France medical devices market size in 2026?',
    answer: 'The French medical devices market is estimated at EUR 14–16 billion in 2026. ANSM (Agence nationale de sécurité du médicament et des produits de santé) is the national competent authority for market surveillance under EU MDR. Medical devices seeking reimbursement through the Assurance Maladie must be listed on the LPP (Liste des Produits et Prestations). HAS CNEDIMTS (Commission nationale d\'évaluation des dispositifs médicaux et des technologies de santé) assesses the ASA (added value) of new devices for LPP listing. The Forfait Innovation pathway enables early conditional reimbursement for genuinely innovative devices.',
  },
  {
    question: 'How does CEPS price negotiation work in France?',
    answer: "CEPS (Comité Économique des Produits de Santé), the French government's pricing committee, negotiates ex-factory prices for all medicines seeking Assurance Maladie reimbursement following HAS Transparency Commission assessment. Statutory negotiation windows run 180 days, though in practice discussions frequently extend to 9–18 months for complex or high-cost products. ASMR ratings from HAS directly shape CEPS's negotiating position: ASMR I–III ratings support premium pricing versus the nearest comparator, while ASMR IV or V ratings typically anchor the price at or below the comparator level. CEPS also references list prices across a basket of roughly eleven other European countries when setting French prices, and increasingly relies on confidential managed-entry agreements, including outcomes-based and volume-capped arrangements, for expensive oncology, rare disease, and gene therapy products. Once CEPS and the manufacturer reach agreement, the price and reimbursement rate are published in the Journal Officiel, which formally triggers Assurance Maladie coverage.",
  },
  {
    question: 'What is ONDAM and how does it affect the France healthcare market?',
    answer: "ONDAM (Objectif National de Dépenses d'Assurance Maladie) is France's annual national target for Assurance Maladie spending, voted each year by Parliament as part of the Social Security financing law (LFSS). ONDAM sets an overall ceiling across hospital care, ambulatory medicine, medico-social services, and pharmaceutical spending, and its year-on-year growth rate — typically in the low single digits — is a closely watched signal of the government's fiscal appetite for healthcare and pharmaceutical spending. When actual spending threatens to breach the ONDAM target, the government and CEPS can respond with price cuts, rebate clawbacks (clause de sauvegarde), and volume-based conventions with manufacturers to bring spending back in line. For pharmaceutical companies, ONDAM pressure has historically translated into more aggressive CEPS price negotiations, faster generic and biosimilar substitution targets, and periodic across-the-board price revision campaigns on mature products.",
  },
  {
    question: "What is France's approach to biosimilar substitution?",
    answer: 'France permits pharmacist-level substitution of biosimilars for reference biologics at the point of treatment initiation, and since 2022 has extended substitution rights to certain products even during ongoing treatment, subject to physician non-objection and patient information. The Assurance Maladie and CEPS actively promote biosimilar uptake through pharmacist substitution incentives, hospital-level prescribing targets embedded in GHT (Groupement Hospitalier de Territoire) formulary policies, and price convergence rules that require biosimilars to launch at a discount to the originator. Biosimilar penetration is most advanced in filgrastim, insulin glargine, and adalimumab, with growing uptake in oncology biosimilars such as trastuzumab, bevacizumab, and rituximab. For manufacturers, biosimilar entry typically triggers CEPS-mandated price reductions on the originator product as well, making the timing of a first biosimilar launch a significant commercial planning variable in France.',
  },
  {
    question: 'How does BioNixus serve France-based pharmaceutical companies expanding to MENA?',
    answer: 'BioNixus supports French and wider European pharmaceutical and medical device companies in expanding into GCC and MENA markets. From our London office, we provide SFDA (Saudi Arabia), MOHAP (UAE), and GCC-wide regulatory pathway intelligence; NUPCO tender intelligence and hospital formulary data; physician panel surveys across all major therapeutic areas in Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, and Egypt; and comparative EU vs. GCC market intelligence for global commercial and market access strategy. BioNixus bridges European evidence standards with GCC commercial realities.',
  },
], 'france');

const REPORT_CONVERSION = getStandaloneReportConfig('/france-healthcare-market-report');
const FAQ_SECTION_ID = 'france-healthcare-market-faq';

const jsonLd = [
  buildBreadcrumbSchema(breadcrumbItems),
  {
    '@context': 'https://schema.org',
    '@type': 'Article',
    headline: 'France Healthcare Market Report 2026: HAS, Assurance Maladie, and Pharmaceutical Market Intelligence',
    author: { '@type': 'Organization', name: 'BioNixus' },
    publisher: { '@type': 'Organization', name: 'BioNixus', logo: { '@type': 'ImageObject', url: 'https://www.bionixus.com/bionixus-logo.webp' } },
    datePublished: '2026-05-27',
    dateModified: '2026-05-27',
    mainEntityOfPage: 'https://www.bionixus.com/france-healthcare-market-report',
  },
  {
    '@context': 'https://schema.org',
    '@type': 'FAQPage',
    url: `https://www.bionixus.com/france-healthcare-market-report#${FAQ_SECTION_ID}`,
    mainEntity: REPORT_FAQ_ITEMS.map((item) => ({ '@type': 'Question', name: item.question, acceptedAnswer: { '@type': 'Answer', text: item.answer } })),
  },
  ...buildReportEnrichmentSchemas({
    pageTitle: "France Healthcare Market Report 2026 | HAS ASMR, Assurance Maladie & Pharma Intelligence | BioNixus",
    pageMetaDescription: "France healthcare market at EUR 260B in 2026. HAS SMR/ASMR assessment, CEPS price negotiation, Assurance Maladie reimbursement, AAP early access, and BioNixus intelligence for French pharma companies expanding to GCC.",
    countryName: "France",
    marketSlug: "france",
    publishedDate: "2026-05-27",
    modifiedDate: "2026-05-27",
  })
];

const FranceHealthcareMarketReport = () => (
  <div className="min-h-screen bg-background">
    <Navbar />
    <SEOHead
      title="France Healthcare Market Report 2026 | BioNixus"
      description="France healthcare market at EUR 260B in 2026. HAS SMR/ASMR assessment, CEPS price negotiation, Assurance Maladie reimbursement, AAP early access, and."
      canonical="https://www.bionixus.com/france-healthcare-market-report"
      jsonLd={jsonLd}
    />
      <ReportReadingProgress progressId="report-rp-france-healthcare-market-report" />
      <main>
      <div className="section-padding pt-24 pb-4"><div className="container-wide"><BreadcrumbNav items={breadcrumbItems} /></div></div>
              <ReportPremiumHero
          title="France Healthcare Market Report 2026: HAS Market Access, Assurance Maladie, and Commercial Intelligence"
          description="BioNixus operates from London, serving French and European pharmaceutical and medical device companies with GCC and MENA market intelligence — and providing France market context for global commercial teams planning EU5 and multi-market strategy."
          config={REPORT_CONVERSION}
          marketSlug="france"
          countryName="France"
          stats={[
            { value: '~€260B', label: 'France healthcare market 2026' },
            { value: '~€33B', label: 'Pharmaceutical market 2026' },
            { value: '~€15B', label: 'Medical devices market 2026' },
          ]}
        />
      <ReportContentWithAside config={REPORT_CONVERSION}>
        <section className="section-padding bg-cream-dark" id="executive-summary">
        <div className="container-wide max-w-4xl mx-auto">
          <h2 className="text-2xl md:text-3xl font-display font-semibold text-foreground mb-6">Executive Summary</h2>
          <div className="bg-white rounded-xl border border-border p-6 shadow-sm mb-6">
            <div className="grid sm:grid-cols-3 gap-6 text-center">
              <div><p className="text-3xl font-display font-bold text-primary">~€260B</p><p className="text-xs text-muted-foreground mt-1">France healthcare market 2026</p></div>
              <div><p className="text-3xl font-display font-bold text-primary">~€33B</p><p className="text-xs text-muted-foreground mt-1">Pharmaceutical market 2026</p></div>
              <div><p className="text-3xl font-display font-bold text-primary">~€15B</p><p className="text-xs text-muted-foreground mt-1">Medical devices market 2026</p></div>
            </div>
          </div>
          <p className="text-muted-foreground leading-relaxed mb-4">France is the EU's second-largest pharmaceutical market and a high-value launch priority for innovative therapies. The HAS SMR/ASMR two-stage assessment framework is Europe's most widely studied HTA model — ASMR ratings directly determine pricing leverage in CEPS negotiations. The Autorisation d'Accès Précoce (AAP) pathway for pre-approval access is among the most active in Europe for oncology and rare diseases. Universal coverage through Assurance Maladie, financed under an annual ONDAM spending ceiling set by Parliament, means pricing and reimbursement outcomes are shaped as much by macro fiscal targets as by individual product value dossiers. France's roughly 3,000 public and private hospitals are organised into regional Groupements Hospitaliers de Territoire (GHT), which coordinate joint formulary adoption once CEPS pricing agreements are published in the Journal Officiel — a structural feature that distinguishes French market access planning from single-payer systems elsewhere in the EU5.</p>
          <p className="text-muted-foreground leading-relaxed">For GCC/MENA intelligence, see our <Link to="/gcc-pharma-market-report-2026" className="text-primary hover:underline font-medium">GCC Pharmaceutical Market Report 2026</Link>.</p>
            <ReportMidPageCta config={REPORT_CONVERSION} className="mt-8" />
        </div>
      </section>

        <MarketIntelligenceSections marketSlug="france" countryName="France" variant="healthcare" />
      <section className="section-padding" id="market-access">
        <div className="container-wide max-w-4xl mx-auto">
          <h2 className="text-2xl md:text-3xl font-display font-semibold text-foreground mb-6">France Pharmaceutical Market Access Framework</h2>
          <div className="space-y-4">
            {[
              { label: 'EMA Approval + Marketing Authorisation', body: 'France accepts EMA centrally authorised products directly. National authorisations go through ANSM. Launch timing is a strategic decision — France is the second-largest EU market and typically among the first four EU5 launches.' },
              { label: 'HAS Transparency Commission (SMR + ASMR)', body: 'SMR determines absolute reimbursement eligibility and coverage rate. ASMR rates added benefit on a five-point scale. ASMR I–III provides pricing leverage in CEPS negotiations; ASMR IV or V results in pricing at or near the comparator level.' },
              { label: 'CEPS Price Negotiation', body: 'CEPS negotiates reimbursement prices based on HAS ratings, international reference pricing, and managed access conditions. Conditional reimbursement agreements (including outcomes-based contracts) are increasingly common for high-cost products.' },
              { label: 'AAP (Autorisation d\'Accès Précoce)', body: 'Pre-approval access framework enabling patients to access promising therapies before marketing authorisation, with manufacturer-funded access until definitive reimbursement decision. AAP is particularly active in oncology, rare diseases, and gene therapy.' },
            ].map(({ label, body }) => (
              <div key={label} className="bg-white rounded-xl border border-border p-5 shadow-sm">
                <h3 className="text-base font-semibold text-foreground mb-2">{label}</h3>
                <p className="text-sm text-muted-foreground leading-relaxed">{body}</p>
              </div>
            ))}
          </div>
        </div>
      </section>
      <section className="section-padding bg-cream-dark" id="payer-reimbursement">
        <div className="container-wide max-w-4xl mx-auto">
          <h2 className="text-2xl md:text-3xl font-display font-semibold text-foreground mb-6">France Payer and Reimbursement Landscape</h2>
          <p className="text-muted-foreground leading-relaxed mb-6">France finances healthcare through a combination of Assurance Maladie (the statutory Sécurité Sociale scheme, sometimes called "la Sécu"), complementary private insurance, and out-of-pocket payment. Understanding how HAS benefit ratings translate into Assurance Maladie coverage rates, and how CEPS pricing interacts with the annual ONDAM budget ceiling, is essential for any company planning a France launch.</p>
          <div className="space-y-4">
            {[
              { label: 'HAS SMR (Service Médical Rendu) Rating Scale', body: 'SMR measures the absolute medical benefit of a product for a given indication on a four-tier scale — substantial, important (modéré), weak (faible), and insufficient. An "insufficient" SMR rating results in reimbursement refusal, regardless of clinical merit elsewhere in the dossier. SMR is reassessed periodically, and products can be downgraded (and their reimbursement rate cut) as newer comparators enter the market or long-term evidence accumulates.' },
              { label: 'ASMR (Amélioration du SMR) Added-Benefit Scale', body: 'ASMR grades the incremental clinical benefit of a new product against the existing standard of care, from ASMR I (major improvement) through ASMR V (no improvement demonstrated). ASMR is the single most important variable in CEPS price negotiations: a high ASMR rating supports premium pricing versus European reference countries, while ASMR V products are typically priced to match the cheapest relevant comparator.' },
              { label: 'Sécurité Sociale Reimbursement Rates', body: 'Assurance Maladie reimburses medicines at statutory rates tied to SMR level — typically 65% for important SMR, 30% for moderate SMR, and 15% for weak SMR, with 100% reimbursement reserved for products treating long-term or serious conditions (Affections de Longue Durée, ALD). Hospital-administered medicines and products on the "liste en sus" are reimbursed separately, outside the standard diagnosis-related-group hospital tariff.' },
              { label: 'Complementary Insurance (Mutuelles) and Patient Out-of-Pocket Costs', body: 'Roughly 95% of the French population holds a complementary mutuelle or private insurance policy that covers some or all of the co-payment left after Assurance Maladie reimbursement, keeping true out-of-pocket exposure for most patients relatively low despite headline reimbursement rates well below 100%. Employer-sponsored complementary coverage has been mandatory for private-sector employees since 2016, further limiting the practical financial barrier to accessing HAS-reimbursed medicines.' },
            ].map(({ label, body }) => (
              <div key={label} className="bg-white rounded-xl border border-border p-5 shadow-sm">
                <h3 className="text-base font-semibold text-foreground mb-2">{label}</h3>
                <p className="text-sm text-muted-foreground leading-relaxed">{body}</p>
              </div>
            ))}
          </div>
        </div>
      </section>
      <section className="section-padding" id="hospital-network">
        <div className="container-wide max-w-4xl mx-auto">
          <h2 className="text-2xl md:text-3xl font-display font-semibold text-foreground mb-6">France Hospital Network Structure</h2>
          <p className="text-muted-foreground leading-relaxed mb-6">France operates roughly 3,000 hospitals with approximately 400,000 beds (around 5.8 beds per 1,000 population), split across university teaching hospitals, general public hospitals, and private facilities operating under public service missions. Since 2016, hospitals have been organised into regional groupings that jointly manage procurement and formulary decisions, which is a key operational detail for companies planning hospital-channel launches.</p>
          <div className="space-y-4">
            {[
              { label: 'CHU / CHR — University and Regional Teaching Hospitals', body: 'France has 32 CHU (Centres Hospitaliers Universitaires) and CHR (Centres Hospitaliers Régionaux), which combine tertiary clinical care, medical education, and research. CHUs are typically the first adopters of innovative and specialist therapies, host most AAP early-access patients, and are the primary sites for oncology, rare disease, and gene therapy administration.' },
              { label: 'CH (General Hospitals) and Private Hospitals Under Public Mission', body: 'Approximately 900 CH (Centres Hospitaliers) provide general acute, emergency, and secondary care across French départements, complemented by roughly 700 private hospitals operating under a public service mission (établissements de santé privés d\'intérêt collectif, ESPIC) that receive comparable public financing and formulary obligations to their public counterparts.' },
              { label: 'GHT (Groupements Hospitaliers de Territoire)', body: 'Since 2016, French public hospitals have been required to join a Groupement Hospitalier de Territoire, a regional grouping that shares a single medical project, joint pharmacy and procurement functions, and — critically for market access — a common hospital drug formulary. A positive formulary decision at the GHT pharmacy and therapeutics committee level is often the practical gateway to hospital-channel uptake across an entire region.' },
              { label: 'AP-HP and Regional Health Agencies (ARS)', body: 'AP-HP (Assistance Publique – Hôpitaux de Paris) is Europe\'s largest hospital group, comprising dozens of hospital sites across the Paris region and acting as a bellwether formulary adopter for innovative therapies nationally. Day-to-day oversight of hospital planning, GHT coordination, and regional health strategy sits with the 18 ARS (Agences Régionales de Santé), which implement national ONDAM and HAS/CEPS decisions at the regional level.' },
            ].map(({ label, body }) => (
              <div key={label} className="bg-white rounded-xl border border-border p-5 shadow-sm">
                <h3 className="text-base font-semibold text-foreground mb-2">{label}</h3>
                <p className="text-sm text-muted-foreground leading-relaxed">{body}</p>
              </div>
            ))}
          </div>
        </div>
      </section>
      <FAQSection sectionId={FAQ_SECTION_ID} title="France healthcare market 2026 — HAS, ASMR, CEPS, Assurance Maladie, and AAP FAQ" items={REPORT_FAQ_ITEMS} className="bg-muted/30" />        </ReportContentWithAside>
      <ReportConsultationBand config={REPORT_CONVERSION} />
        </main>
    <Footer />
  </div>
);

export default FranceHealthcareMarketReport;
